Key Strategies in Market Access for Digital Therapeutics

Chronic anxiety disorders like panic attacks, panic disorder, and PTSD affect millions, straining individuals, caregivers, and healthcare systems. Freespira introduces the first FDA-cleared, at-home, medication-free digital therapeutic that combines advanced technology with personalized coaching to deliver accessible, effective, and cost-saving treatment. Clinical studies highlight impressive outcomes: over 80% of patients experience significant symptom reduction in just 28 days, with sustained benefits and high adherence rates. By leveraging innovative market access strategies, robust stakeholder engagement, and a patient-centered approach, Freespira sets a new standard for mental health care—empowering patients, reducing costs, and expanding access to life-changing treatment.